The purpose of this study is to determine whether patients with high-risk smoldering multiple myeloma when treated with daratumumab in addition to lenalidomide and dexamethasone live longer when compared to patients with high-risk smoldering multiple myeloma treated with lenalidomide and dexamethasone.
Learn more about the EAA173 trial or call the Cancer Research Office at Pottstown Hospital (610-327-7772) or Reading Hospital (484-628-8193).
